Biology moves in phases. Medicine should too.
Phasecyte is building a new class of mRNA therapeutics: designed to instruct cells in sequence, in context, and in time. We're developing them here, on Australian soil.
01
Phase completes
One cell population does its job and hands over.
02
Cue is given
The next population receives the signal it was waiting for.
03
Phase stalls
A phase doesn't complete, and the system gets stuck there.
04
Never reached
Downstream stages wait on a handover that never arrives.
The problem
Complex chronic disease isn't one broken mechanism.
It's a web of them. Several systems failing at once, each one reinforcing the others, playing out over months and years rather than minutes.
Most therapies are built for a different shape of problem. They hold one target steady and hope the rest of the system follows. In complex chronic disease it usually doesn't, because the sequence is disrupted and stuck in a dysfunctional state.
That's the gap Phasecyte was founded to close.
The approach
Phase therapeutics
mRNA lets us hand a cell a set of instructions, then let them expire. That allows us to do what a fixed-target drug can't: change the instruction as the biological context progresses.
01
Sequential
Deliver the right functional support at the right phase, then move to the next. Timed expression, in the order the biology actually needs it.
02
Multi-mechanism
Address several interlocking failures together rather than betting the outcome on one pathway.
03
Transient by design
mRNA acts without needing access to the cell's DNA. Effects are temporary, tunable, and repeatable.
Placeholder — lab work at CoLabs, or a Melbourne research precinct (portrait)
Sovereign capability
Australian science, Australian medicines.
Australia produces research and clinical standards that rival anywhere in the world. What it struggles to do is translate that research into medicines domestically. Discoveries made here are routinely developed, manufactured, and commercialised somewhere else.
The new national investments in mRNA infrastructure are enabling the Australian capacity to explore this next generation of therapeutics.
Phasecyte is part of this frontier.
Mission
To develop the next generation of mRNA therapeutics for Australia.
Vision
Transform the way we treat complex diseases by applying systems-level thinking to reprogram cell behaviour and achieve dynamic control over fundamental biological mechanisms.
Where we are
Early, and moving.
- Founded
- March 2026
- Stage
- Preclinical
- Base
- PC2 facility, Melbourne
Our lead program is in active validation, with outcome measures staged across the next twelve months. We're speaking with investors and grant funders now about the work that follows.
Who we are
Our team.
Placeholder — portrait, matching treatment
Co-founder & Chief Executive Officer
Megan Booth
Meg is a business and technology strategist with seven years' experience reshaping how large and complex organisations run, including six years focused on the health sector.
She holds a Bachelor of Business from the University of South Australia and is a member of Mensa Australia. Her career has moved through business strategy consulting, statewide operations management, and enterprise AI transformation, each drawing on a specialisation in systems-level thinking: interrogate the process, question what exists out of habit, and rebuild it to produce real outcomes without losing sight of the true end goal.
At Phasecyte, she leads the business unit, building the operational foundation that lets the science move.
Placeholder — environmental portrait, lab
CO-FOUNDER & CHIEF SCIENTIFIC OFFICER
Khalia Primer, PhD
Khalia is a biochemist with technical skills including molecular cloning, vector construction, viral production, and in vivo delivery, with a specialisation in cellular metabolic reprogramming and mitochondrial bioenergetics that underpins Phasecyte's scientific thesis.
She holds a PhD in Biochemistry from the University of Adelaide and is completing a Doctor of Medicine at the University of Melbourne. In 2024, she was a visiting researcher at the Fraunhofer Institute for Cell Therapy and Immunology in Leipzig, Germany, where she gained a foundation in the computational work now driving Phasecyte's therapeutic platform. Her work is published in Arteriosclerosis, Thrombosis, and Vascular Biology, among others.
Supported by and working with
Phasecyte's early research is supported by a Primordia grant and runs from CoLabs Australia in Brunswick, Victoria.
We're at the point where the next round of evidence needs backing.
If you fund early biotech, run a grant program, or build the infrastructure this kind of work depends on, we'd like to talk.